Project cancellations dominate Kendle’s gloomy Q1 forecast

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization

US firm Kendle is the latest CRO to revise its forecast and blame “unprecedented biopharmaceutical industry conditions,” which are fast becoming an industry catchphrase, for its Q1 woes.

In an echo of statements made by rival PPD, Kendle said that a higher than expected project cancellation rate and delays in signing replacement deals would cause it to miss Q1 estimates.

In a US Securities and Exchange Commission (SEC) filing submitted yesterday, the contract research organisation (CRO) attributed the shortfall to a 45 per cent project cancellation rate, citing a contract lost in February as a major factor.

The Cincinnati-based firm went on to say that a slight upturn in the number of clients proposing projects in January and February had tailed off severely in March, eventually ending the month at the lowest level for a year.

While Kendle is not due to report full Q1 figures until May 7, it did explain that sales for the opening three months of the year are well below expectations with its Phase II and III business being hit most severely.

The firm’s share price plunged 61 per cent to a four year low of $8.28 when the news broke, eventually climbing back to $10.26 in afternoon trading.

In a conference call held on Monday, CEO Candance Kendle said that growing competition was putting pressure on prices, explaining that “while we have worked to pull costs out of the system… we did not shift quickly enough in recent weeks to improve sales​.”

CRO sector struggles in Q1

While Kendle slump was the largest, the firm’s gloomy outlook had a knock on impact on many of its fellow CROs. Parexel’s share price fell 15 per cent to $9.48 while Icon’s dropped 7.8 per cent to $16.90. In addition, Covance and PPD fell 3.5 per cent and 5.7 per cent respectively.

The drug industry’s current focus on M&A rather than R&D has seen a dramatic decline in the number of clinical trials being begun, which is an obvious problem for the CRO industry as a whole.

In a note to investors Alexander Draper from Raymond James said that cancellations may be hitting Kendle harder than other late stage development firms.

Jefferies & Co analyst David Windley agreed. He suggested to the Wall Street Journal​ that although “the issues raised by Kendle appear to be industry wide… they could be affecting Kendle more severely since the company is smaller than its peers​.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more